Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T – In-PharmaTechnologist.com
|
Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR T
In-PharmaTechnologist.com Gilead will also add a chimeric antigen receptor (CAR) T-cell manufacturing facility in El Segunda, California which opened in June last year and has the capacity to produce volumes of the autologous therapy for up to 4,000-5,000 patients per year. |
